Ipsen Stock price

Equities

IPN

FR0010259150

Pharmaceuticals

Real-time Euronext Paris 05:27:55 22/02/2024 pm IST 5-day change 1st Jan Change
102.5 EUR -1.25% Intraday chart for Ipsen -2.38% -5.00%

Financials

Sales 2024 * 3.44B 3.73B 309B Sales 2025 * 3.67B 3.98B 330B Capitalization 8.57B 9.3B 771B
Net income 2024 * 663M 719M 59.61B Net income 2025 * 736M 798M 66.17B EV / Sales 2024 * 2.33 x
Net cash position 2024 * 571M 620M 51.34B Net cash position 2025 * 1.19B 1.3B 107B EV / Sales 2025 * 2.01 x
P/E ratio 2024 *
12.9 x
P/E ratio 2025 *
11.7 x
Employees 5,325
Yield 2024 *
1.14%
Yield 2025 *
1.17%
Free-Float 41.52%
More Fundamentals * Assessed data
Dynamic Chart
1 day-1.06%
1 week-2.19%
Current month-4.02%
1 month-3.66%
3 months-1.72%
6 months-12.07%
Current year-4.82%
More quotes
1 week
102.10
Extreme 102.1
108.50
1 month
100.20
Extreme 100.2
109.70
Current year
100.20
Extreme 100.2
110.60
1 year
99.90
Extreme 99.9
130.70
3 years
65.90
Extreme 65.9
130.70
5 years
34.20
Extreme 34.2
130.70
10 years
28.24
Extreme 28.235
155.95
More quotes
Managers TitleAgeSince
Chief Executive Officer 56 01/20/01
Director of Finance/CFO 54 03/14/03
Chairman 65 22/10/22
Members of the board TitleAgeSince
Director/Board Member 66 07/17/07
Director/Board Member 61 21/22/21
Director/Board Member 65 27/15/27
More insiders
Date Price Change Volume
22/24/22 102.5 -1.25% 15 214
21/24/21 103.8 -1.70% 87,864
20/24/20 105.6 -0.47% 66,330
19/24/19 106.1 +1.14% 52,385
16/24/16 104.9 -0.10% 122,660

Real-time Euronext Paris, February 22, 2024 at 05:06 pm IST

More quotes
Ipsen specialises in the research, development, manufacture and marketing of specialty medicines. Net sales by therapeutic area break down as follows: - oncology (78.6%); - neuroscience (20%); - rare diseases (1.4%). At the end of 2022, the group had 4 research and development centres located in France, the United Kingdom, the United States and China, and 4 manufacturing sites worldwide. Net sales (excluding divested operations) are distributed geographically as follows: Europe (40.9%), North America (34.1%) and other (25%). In July 2022, the group divested its family health products manufacturing business.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
15
Last Close Price
103.8 EUR
Average target price
124.8 EUR
Spread / Average Target
+20.26%
Consensus
1st Jan change Capi.
-4.82% 9 271 M $
+27.96% 671 B $
+21.42% 538 B $
+1.24% 382 B $
+17.52% 325 B $
+13.02% 309 B $
-5.99% 211 B $
+6.40% 209 B $
-6.68% 198 B $
-3.89% 156 B $
Other Pharmaceuticals
  1. Stock
  2. Equities
  3. Stock Ipsen - Euronext Paris
+229% on MICROSOFT CORPORATION since our purchase on January 11, 2019
Replicate our performance
fermer